A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.

Status:
Completed

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

The purpose of this study is to determine if a single dose of AMG 282 is safe in healthy subjects and subjects with mild atopic asthma.

Phase 1

Amgen